HEMO

Hemogenyx Pharmaceuticals PLC

Health Care First-pass screen £43m

250/1000 Overall fit

AI beneficiary 35% 20

Operating leverage 25% 28

Valuation 25% 30

Downside protection 15% 25

First-pass take

CAR-T immunotherapy company with zero AI exposure. Despite Phase 1 efficacy signals for HG-CT-1, pre-commercial status, £9.8m annual loss, and dependency on continued capital raises create execution risk.

Flags

loss-makingclinical-stagekey-person-riskno-valuation-datamicro-cap